SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2013 / Cilt: 43 - Sayı: 3

Asymmetric dimethylarginine levels in allergic rhinitis and nasal polyposis

Tayfun APUHAN
Mehmet TOSUN
Pages
455–458
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In the present study, lower ADMA levels were found in the AR and NP groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Asymmetric dimethylarginine (ADMA) is the major endogenous inhibitor of nitric oxide synthase.
📊
Key Findings & Data:Materials and methods: A total of 29 AR patients, 21 NP patients, and 30 healthy subjects to be used as a control group were enrolled in the study.
💡
Conclusion & Impact:Conclusion: In the present study, lower ADMA levels were found in the AR and NP groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Asymmetric dimethylarginine · allergic rhinitis · nasal polyposis

Abstract

Asymmetric dimethylarginine (ADMA) is the major endogenous inhibitor of nitric oxide synthase. We aimed to investigate the ADMA levels in allergic rhinitis (AR) and nasal polyposis (NP). Materials and methods: A total of 29 AR patients, 21 NP patients, and 30 healthy subjects to be used as a control group were enrolled in the study. ADMA was measured in the AR, NP, and control groups with enzyme-linked immunosorbent assay. Any patients or control subjects with coronary artery disease, renal failure, diabetes mellitus, or hypertension were excluded from the study. Results: The mean ADMA serum concentration was 0.52 ± 0.08 µmol/L in the AR group, 0.62 ± 0.10 µmol/L in the NP group, and 0.67 ± 0.09 µmol/L in the control group. The ADMA serum concentration in the AR group was significantly lower than in the control group (P < 0.001). Considered together, the NP and AR groups had ADMA levels that were significantly lower than in the control group (P < 0.001). Conclusion: In the present study, lower ADMA levels were found in the AR and NP groups.

Özet

Asymmetric dimethylarginine (ADMA) is the major endogenous inhibitor of nitric oxide synthase. We aimed to investigate the ADMA levels in allergic rhinitis (AR) and nasal polyposis (NP). Materials and methods: A total of 29 AR patients, 21 NP patients, and 30 healthy subjects to be used as a control group were enrolled in the study. ADMA was measured in the AR, NP, and control groups with enzyme-linked immunosorbent assay. Any patients or control subjects with coronary artery disease, renal failure, diabetes mellitus, or hypertension were excluded from the study. Results: The mean ADMA serum concentration was 0.52 ± 0.08 µmol/L in the AR group, 0.62 ± 0.10 µmol/L in the NP group, and 0.67 ± 0.09 µmol/L in the control group. The ADMA serum concentration in the AR group was significantly lower than in the control group (P < 0.001). Considered together, the NP and AR groups had ADMA levels that were significantly lower than in the control group (P < 0.001). Conclusion: In the present study, lower ADMA levels were found in the AR and NP groups.

🔖

Cite This Article

APUHAN, T., TOSUN, M. (2022). Asymmetric dimethylarginine levels in allergic rhinitis and nasal polyposis. Turkish Journal of Medical Sciences, Cilt: 43 - Sayı: 3, 455–458. https://ajindex.com/articles/611056

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Mucci T, Govindaraj S, Tversky J. Allergic rhinitis. Mt Sinai J Med 2011; 78: 634–44. Naclerio RM. Allergic rhinitis. N Engl J Med 1991; 325: 860–9. Bernstein JM. Update on the molecular biology of nasal polyposis. Otolaryngol Clin North Am 2005; 38: 1243–55. Drake-Lee A. The pathogenesis of nasal polyps. In: Settipane G, Lund VJ, Bernstein JM, Tos M, editors. Nasal polyps: epidemiology, pathogenesis and treatment. Providence, RI, USA: Oceanside Publications; 1997. p.57–64.
  2. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl 2007: 1–1
  3. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–42.
  4. Kaplan İ, Aydın Y, Bilen Y, Genç F, Keleş MS, Eroğlu A. The evaluation of plasma arginine, arginase, and nitric oxide levels in patients with esophageal cancer. Turk J Med Sci 2012; 42: 403–409.
  5. Arnal JF, Didier A, Rami J, M’Rini C, Charlet JP, Serrano E et al. Nasal nitric oxide is increased in allergic rhinitis. Clin Exp Allergy 1997; 27: 358–62.
  6. Silkoff PE, Chatkin J, Qian W, Chakravorty S, Gutierrez C, Furlott H et al. Nasal nitric oxide: a comparison of measurement techniques. Am J Rhinol 1999; 13: 169–78.
  7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20: S60–2. Klein E, Weigel J, Buford MC, Holian A, Wells SM. Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma. Am J Physiol Lung Cell Mol Physiol 2010; 299: L816–25. Wells SM, Buford MC, Migliaccio CT, Holian A. Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice. J Respir Cell Mol Biol 2009; 40: 179–88.
  8. Scott JA, North ML, Rafii M, Huang HL, Pencharz P, Subbarao P et al. Asymmetric dimethylarginine is increased in asthma. Am J Resp Crit Care 2011; 184: 779–85.
  9. Alcelik A, Ozhan H, Alcelik AG, Yalcin S, Aydin Y. Asymmetric dimethyl arginine level as a cardiovascular risk factor in patients with hyperthyroidism. Acta Endocrinol (Buc) 2012; 8: 27– Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010; 6: 82–90.
  10. Kökçam İ, Dertlioğlu SB. The levels of nitric oxide and metabolites in Behçet’s disease. Turk J Med Sci 2011; 41: 587–94.
  11. Bakkeheim E, Mowinckel P, Carlsen KH, Burney P, Carlsen KC. Altered